Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Immunological Mechanisms Involved In Experimental Peptide Immunotherapy of T-Cell-Mediated Diseases
RESUMO
Current therapies for autoimmune diseases and allergy involve general immune suppression. However, the ideal therapy should specifically eliminate or modulate the (auto)pathogenic immune response or, alternatively, it should reinforce the regulatory response, without affecting the overall function of the immune system. This could be achieved by antigen-specific immunotherapy. Antigen-specific immunotherapy has received ample attention in the last years, and several clinical trials attempting to treat autoimmune diseases or allergy through the induction of antigen-specific tolerance or immune deviation have been conducted, albeit with varying success. Recent advances in our understanding of peripheral tolerance, regulatory T cells, and routes of antigen administration have resulted in better insight into the different working mechanisms and potential target molecules of antigen-specific immunotherapy. The experimental animal models and new technological developments force the pace in the development of these immunotherapies. The current review addresses several aspects of antigen-specific immunotherapies and focuses on the mechanisms of the different approaches in experimental autoimmune and allergy models.
-
Yang Lin, Jiang Hua, Shi Bizhi, Wang Huamao, Li Jinjun, Wang Hai, Yao Ming, Li Zonghai, Identification and characterization of Ch806 mimotopes, Cancer Immunology, Immunotherapy, 59, 10, 2010. Crossref
-
Massey Emma J, Sundstedt Anette, Day Michael J, Corfield Gaynor, Anderton Stephen, Wraith David C, Intranasal peptide-induced peripheral tolerance: the role of IL-10 in regulatory T cell function within the context of experimental autoimmune encephalomyelitis, Veterinary Immunology and Immunopathology, 87, 3-4, 2002. Crossref
-
Knittelfelder Regina, Riemer Angelika B, Jensen-Jarolim Erika, Mimotope vaccination – from allergy to cancer, Expert Opinion on Biological Therapy, 9, 4, 2009. Crossref
-
Prakken Berent J., Roord Sarah, Van Kooten Peter J. S., Wagenaar Jos�e P. A., Van Eden Willem, Albani Salvatore, Wauben Marca H. M., Inhibition of adjuvant-induced arthritis by interleukin-10-driven regulatory cells induced via nasal administration of a peptide analog of an arthritis-related heat-shock protein 60 T cell epitope, Arthritis & Rheumatism, 46, 7, 2002. Crossref
-
Riemer Angelika B., Kurz Harald, Klinger Markus, Scheiner Otto, Zielinski Christoph C., Jensen-Jarolim Erika, Vaccination With Cetuximab Mimotopes and Biological Properties of Induced Anti–Epidermal Growth Factor Receptor Antibodies, JNCI: Journal of the National Cancer Institute, 97, 22, 2005. Crossref
-
Shi Xiao-Lian, Wang Li-Ping, Feng Xuan, Fan Dan-Dan, Zang Wei-Jin, Wang Bing, Zhou Jun, Inhibition of adjuvant-induced arthritis by nasal administration of novel synthetic peptides from heat shock protein 65, BMC Musculoskeletal Disorders, 15, 1, 2014. Crossref
-
Angelini Giovanni, Bonamonte Domenico, Lucchese Alberta, Favia Gianfranco, Serpico Rosario, Mittelman Abraham, Simone Simone, Sinha Animesh A, Kanduc Darja, Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report, Journal of Translational Medicine, 4, 1, 2006. Crossref
-
GARMAN R D, MUNROE K, RICHARDS S M, Methotrexate reduces antibody responses to recombinant human α-galactosidase A therapy in a mouse model of Fabry disease, Clinical and Experimental Immunology, 137, 3, 2004. Crossref